#USA #Houston #Rice University #HOBIT System #Implantable Therapies

Transforming Drug Delivery with the HOBIT System

In recent years, the medical field has seen a surge in interest surrounding the use of living cells for drug production, commonly known as cell-based therapy. These therapies have the potential to revolutionize the treatment landscape for myriad diseases, ranging from diabetes to cancer. However, one significant challenge remains: ensuring that a sufficient quantity of living cells can be implanted effectively while maintaining their viability and functionality. Researchers at Rice University, in collaboration with Carnegie Mellon University and Northwestern University, have taken a significant step towards overcoming this obstacle with their innovative Hybrid Oxygenation Bioelectronics system for Implanted Therapy—affectionately known as HOBIT.

Understanding HOBIT

The HOBIT system is designed to be implanted under the skin through minimally invasive surgery, aiming to deliver a sustainable solution for drug therapy. Traditional methods often fell short, especially in providing the adequate oxygen supply required for cell clusters to function efficiently. According to Chris Wright, a Ph.D. student at Rice University, when cells are densely packed, they naturally compete for oxygen, which is particularly challenging in less vascularized areas like subcutaneous tissues. The HOBIT addresses this critical challenge by incorporating a sophisticated system that not only protects the cells but also ensures they receive the necessary nutrients and oxygen.

HOBIT integrates a miniaturized electrocatalytic oxygenator that functions as a localized oxygen generator. Utilizing an iridium oxide-based surface and an onboard battery, this device splits water from the surrounding tissue to produce oxygen, thereby circumventing harmful byproducts that typically arise from other oxygen-generating processes. Tzahi Cohen-Karni, a distinguished professor of materials science and biomedical engineering, remarked on the unique blend of energy research and bioengineering that this project embodies, showcasing a remarkable advancement in the field of drug delivery systems.

Revolutionary Design

What makes HOBIT particularly groundbreaking is its compact design. Scaled to roughly the size of a folded stick of gum, it houses a specially designed cell chamber that not only insulates the cells from the host immune system but also allows for the unimpeded flow of necessary nutrients and biologics. This is achieved through a two-stage encapsulation method where engineered cells are microencapsulated in alginate hydrogel beads before being loaded into a larger chamber equipped with a semipermeable membrane.

The versatility of HOBIT is highlighted by its ability to produce multiple biologic molecules concurrently. The encapsulated cells are engineered to continuously generate three distinct biologics, which include an antibody, a hormone, and exenatide—an analog of GLP-1. This simultaneous production is not only a technological advancement but also opens avenues for more sophisticated therapies that require less frequent dosages.

Proof of Concept and Future Applications

Recent studies conducted to evaluate the performance of the HOBIT devices illustrate the potential for practical application. The team implanted both oxygenated and control devices in rats over a 30-day period. Results were promising, revealing sustained levels of biologics in those receiving oxygenated installations. Notably, while short-half-life biologics were undetectable by day seven in control devices, the oxygenated implants maintained performance significantly longer. At the conclusion of the testing period, about 65% of the cells in HOBIT devices remained viable, compared to just 20% in the control devices.

As the research team looks ahead, they plan to conduct studies in larger animal models focusing on disease-specific applications, with diabetes being a primary target—especially given the organ's variable oxygen demands. The research team is actively pursuing partnerships and funding to transition their findings into clinical applications.

Omid Veiseh, a bioengineering professor and lead on the project, emphasized the groundbreaking nature of their work, highlighting that HOBIT brings them closer to a feasible clinical platform. The prospect of a single implant that continuously produces biologics could drastically alter the therapeutic landscape, providing more efficient, effective, and patient-friendly treatment options.

With the successes of the HOBIT system, the future of cell-based therapy appears more viable than ever. As the scientific community continues to unpack these developments, the possibilities for innovative treatments seem boundless.